March 22, 2022 01:54 PM EDTUpdated March 25, 11:49 AM

Fujifilm expands C&G therapy options with acquisition of recombinant protein maker

Josh Sullivan

Fujifilm is expanding its footprint within the US yet again, this time with another East Coast acquisition within driving distance of its new $2 billion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Fujifilm expands C&G therapy options with acquisition of recombinant protein maker

Josh Sullivan

Sign up to read this article for free.

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Fu­ji­film ex­pands C&G ther­a­py op­tions with ac­qui­si­tion of re­com­bi­nant pro­tein mak­er

Josh Sullivan

Sign up to read this article for free.

more like this

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Fujifilm expands C&G therapy options with acquisition of recombinant protein maker

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout